The expression of CB1 and CB2 in human glioblastoma cell lines and tumor-derived cultures prompted us to investigate whether these cells would respond to cannabinoids and to what extent susceptibility to cannabinoids would be affected by TP53 and PTEN defects. The gene discussed is CNR2; the disease is glioblastoma.